Fig. 2
(a) Outcomes of COVID-19 in all patients treated with obinutuzumab or rituximab. (b) Subgroup analysis of the COVID-19 outcomes in patients who had not received bendamustine
Fig. 2 | Virology Journal
(a) Outcomes of COVID-19 in all patients treated with obinutuzumab or rituximab. (b) Subgroup analysis of the COVID-19 outcomes in patients who had not received bendamustine
Virology Journal